MAOB and Parkinson disease: Last-generationMAO-Is, which are selective and reversible, show fewer side effects.Reversible and selective MAO-A inhibitors are currently utilized asa third/fourth-line treatment for depressive disorders (e.g., moclobemide),whereas some irreversible and selective MAO-B inhibitors are usedas monotherapy or as L-DOPA adjuvants (e.g., selegiline and rasagiline)in the treatment of PD.8